Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last481 to 500 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation | 473 of 8,803 608 of 8,801 | -1.5 points -2.2 to -0.8 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit | 97 of 8,803 122 of 8,801 | -0.3 points -0.6 to 0.0 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomization to First Occurrence of a Composite Outcome Measure Consisting of: Cardiovascular (CV) Death, Non-fatal Myocardial Infarction (MI), or Non-fatal Stroke | 569 of 8,803 701 of 8,801 | -1.5 points -2.3 to -0.7 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal Stroke | 154 of 8,803 165 of 8,801 | -0.1 points -0.5 to 0.3 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Outcome Measure Consisting of: All-cause Death, Non-fatal MI, or Non-fatal Stroke | 710 of 8,803 877 of 8,801 | -1.9 points -2.7 to -1.1 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a 5-component Composite Nephropathy Outcome Measure | 155 of 8,803 198 of 8,801 | -0.5 points -0.9 to -0.1 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to CV Death | 223 of 8,803 262 of 8,801 | -0.4 points -0.9 to 0.0 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of UAP Requiring Hospitalisation | 109 of 8,803 124 of 8,801 | -0.2 points -0.5 to 0.2 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Non-fatal MI | 234 of 8,803 322 of 8,801 | -1.0 points -1.5 to -0.5 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of an Expanded Composite CV Outcome Measure Consisting of: CV Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularisation or Unstable Angina Pectoris (UAP) Requiring Hospitalisation | 873 of 8,803 1,074 of 8,801 | -2.3 points -3.2 to -1.4 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: deaths from any cause | 371 of 8,803 460 of 8,801 | -1.0 points -1.6 to -0.4 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of a Composite Heart Failure (HF) Outcome Measure Consisting of: HF Hospitalisation, Urgent HF Visit or CV Death | 300 of 8,803 361 of 8,801 | -0.7 points -1.3 to -0.1 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to All-cause Death | 375 of 8,803 458 of 8,801 | -0.9 points -1.6 to -0.3 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: serious adverse events | 2,941 of 8,803 3,204 of 8,801 | -3.0 points -4.4 to -1.6 | 17,604 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Glycosylated Haemoglobin (HbA1c) Greater Than Equals to (≥) 48 Millimole Per Mole (mmol/Mol) (6.5 Percentage [%]) | 306 of 8,800 1,059 of 8,797 | -8.6 points -9.3 to -7.8 | 17,597 | NCT03574597 Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity |
| ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness With Any Hospice Enrollment | 373 of 5,766 832 of 11,782 | -0.6 points -1.4 to 0.2 | 17,548 | NCT02612688 Pragmatic Trial of Video Education in Nursing Homes |
| ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness Receiving Any Burdensome Treatment | 465 of 5,766 1,028 of 11,782 | -0.7 points -1.5 to 0.2 | 17,548 | NCT02612688 Pragmatic Trial of Video Education in Nursing Homes |
| ACP Video Program vs Usual ACP Procedures: Proportion of Long-stay Residents Without Advanced Illness That Has Medicare ACP Billing Codes | 571 of 5,766 1,157 of 11,782 | 0.1 points -0.8 to 1.0 | 17,548 | NCT02612688 Pragmatic Trial of Video Education in Nursing Homes |
| Zoster-022/006 Pooled GSK1437173A Group vs Zoster-022/006 Pooled Placebo Group: Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs | 128 of 8,758 144 of 8,773 | -0.2 points -0.5 to 0.2 | 17,531 | NCT01165229 Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older |
| S-268019-b vs Placebo: deaths from any cause | 29 of 9,083 29 of 8,435 | -0.0 points -0.2 to 0.1 | 17,518 | NCT05212948 A Study of S-268019 for the Prevention of COVID-19 |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=25
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03574597-0c2be2f1",
"title": "Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of Coronary Revascularisation",
"summary": "473 of 8803 against 608 of 8801; risk difference -1.5 points, 95% interval -2.2 to -0.8; NCT03574597, Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity",
"record": "/library/comparisons/NCT03574597-0c2be2f1",
"nct_id": "NCT03574597",
"kind": "outcome",
"participants": 17604,
"risk_difference": {
"value": -0.015351376362318155,
"lower": -0.02246055340225811,
"upper": -0.00826445609801518
},
"group_1": "473 of 8,803",
"group_2": "608 of 8,801",
"difference": "-1.5 points",
"interval": "-2.2 to -0.8",
"trial_title": "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity"
},
{
"id": "NCT03574597-19f20c85",
"title": "Semaglutide vs Placebo: Participants From Time of Randomisation to First Occurrence of HF Requiring Hospitalisation or Urgent HF Visit",
"summary": "97 of 8803 against 122 of 8801; risk difference -0.3 points, 95% interval -0.6 to 0.0; NCT03574597, Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity",
"record": "/library/comparisons/NCT03574597-19f20c85",
"nct_id": "NCT03574597",
"kind": "outcome",
"participants": 17604,
"risk_difference": {
"value": -0.0028430903240098636,
"lower": -0.00616028139390796,
"upper": 0.00044218503694354056
},
"group_1": "97 of 8,803",
"group_2": "122 of 8,801",
"difference": "-0.3 points",
"interval": "-0.6 to 0.0",
"trial_title": "Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=26",
"request_id": "A9c9_jMStlQtjCsF"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant